Hikal Q1FY27: consolidated loss narrows to ₹7.4 Cr YoY as margins expand, revenue up 6%
PAT +67% YoY · revenue +5.9% · margins expanding
₹402.8 Cr
+5.9% YoY
₹-7.4 Cr
+67% YoY
-1.83%
+4pp YoY
₹-0.6
Hikal's consolidated Q1 FY27 revenue rose 5.9% YoY to ₹402.8 Cr (₹403 Cr per management's release) but fell 22.4% QoQ from the seasonally heavier ₹519.4 Cr booked in Q4 FY26. The company posted a consolidated net loss of ₹7.4 Cr, narrower than the ₹22.4 Cr loss a year ago and a swing from the ₹14.4 Cr profit in Q4 FY26. NPM was -1.8%, improved from -5.9% YoY but down from +2.7% in Q4. No consensus/Street estimates for this quarter turned up in available previews, so the print cannot be benchmarked against Street numbers; management's own release headlined revenue and a 260 bps YoY EBITDA margin expansion without flagging the continuing bottom-line loss.
Q1 FY-2027 vs prior quarters
The quarter was flattered by a ₹8.9 Cr exceptional gain (restructured salary components reduced a labour-code related liability); stripping this out, the pre-exceptional PBT loss was ₹18.8 Cr — still narrower than the ₹30.4 Cr adjusted loss a year ago (~27% improvement) but far more modest than the 67% narrowing the reported PAT shows. By segment, Pharmaceuticals turned a ₹7.5 Cr profit on ₹233.3 Cr revenue while Crop Protection swung to a ₹6.0 Cr segment loss on ₹169.5 Cr revenue versus a ₹17.3 Cr profit a year ago, reversing the mix that supported FY26. Finance costs (₹14.9 Cr) and depreciation (₹42.7 Cr) remain a heavy drag below the operating line. This sits against May 2026 guidance for a stronger FY27 on positive volume growth and margins sustaining at improved levels through operating leverage — the YoY margin expansion is broadly consistent with that framing, but the ongoing net loss and the Crop Protection swing to a loss fall short of a 'stronger year' start. The USFDA warning letter on the Jigani facility (since August 2025) continues to weigh on Pharma segment sales, per the company's own disclosure.
The stock went into the print at ₹221.43, down 3.2% over the past month of trading.
Management anticipates FY27 to be a stronger year than FY26, driven by improving demand visibility across both pharmaceutical and crop protection businesses. While specific quantitative guidance for FY27 revenue and margins was deferred to the Q1 call due to ongoing global uncertainties, they project positive volume gr
— This quarter: met
W1
Whether Crop Protection returns to profit next quarter (Q1 FY27 segment loss ₹6.0 Cr vs ₹17.3 Cr profit YoY)
W2
EBITDA margin trajectory following the 260 bps YoY expansion management flagged this quarter
W3
Resolution timeline of the USFDA warning letter on the Jigani Pharma facility and its sales impact
Figures in Rs Million in source, converted /10 to Cr; current quarter carries a Rs 8.9 Cr exceptional gain (salary-component restructuring reduced a labour-code liability) vs no exceptional item a year ago, and vs a Rs 47.1 Cr impairment exceptional charge in Q4 FY26; standalone (-7.5 Cr) and consolidated (-7.4 Cr) PAT diverge <2%, not material.
Recovery On Track, But Leverage and Crop Headwinds Cloud the Outlook
Q1 net loss of ₹7.4 crore masks a stable EBITDA margin of 9.2%. The real story: high debt and a Crop division under structural pressure are obscuring Pharma's genuine momentum.
-₹7.4 Cr
Net loss (trough quarter)
₹37 Cr (9.2%)
Stable QoQ; operations solid
₹50Cr+ annually
On ₹685Cr net debt (D/E 0.53)
₹233 Cr
YoY growth despite FDA
On the surface, a ₹7.4 crore net loss looks like a stumble. But the market should read this more carefully. Hikal delivered a stable 9.2% EBITDA margin — the real profit engine is running fine. The loss is almost entirely a leverage story: ₹50 crores in annual interest on ₹685 crores of net debt is eating the bottom line. Separate the debt from the operations, and Q1 tells a messier but more honest story: Pharma is recovering, Animal Health is scaling, Personal Care just launched. But Crop is weak, Q1 was a trough due to the planned FDA shutdown, and the street has noticed — FII ownership has collapsed from 5.36% to just 0.99% in one year.
Where the loss came from — and what it isn't
The Pharma division posted ₹233 crore in revenue with an EBIT margin of 3.2% — respectable given the FDA shutdown blanketed the quarter. Capacity utilization is only 55–60%, reflecting the planned remediation hiatus; once clearance comes (expected year-end), that facility utilization should ramp smartly. Animal Health is humming — the division hit ₹100 crore+ in FY26 run-rate and is driving repeat orders from global innovators. Personal Care just started commercial production at the Panoli facility, zero revenue in Q1 but expected to begin shipping by year-end. The real drag is Crop Protection: ₹170 crore in revenue but an EBIT loss of ₹6 crore due to ₹7–8 crore in raw material and energy cost headwinds. Management acknowledges this division faces structural headwinds — end-customers (5–6 big players controlling 80% of the market) are weak, Chinese competition is intense, and pricing pass-through is limited.
Pharma delivered YoY growth despite FDA shutdown
Pharma ₹233Cr (Q1 transition quarter); overall revenue +5.9% YoY confirms Pharma outpaced Crop
Supported
Zero customer losses; 86 audits, re-approvals by all 3 global regulatory bodies
No contradicting evidence. Documented re-approvals and audit completions.
Supported
FY27 growth 14–16%, EBITDA growth 25–30%, driven by Pharma + Animal Health + Personal Care
Q1 is trough at 5.9% YoY. Q2+ recovery critical to guidance. Conditional on CDMO ramp, Crop stabilization, Personal Care launch.
Mixed — execution dependent
Improving product mix and gross margins for Pharma division
Divisional margins may improve, but company EBITDA is held flat by ₹50Cr+ interest on ₹685Cr debt. Leverage is the margin drag.
Mixed — divisional yes, company-wide masked by debt
What changed on this call
Crop Protection downgraded. In FY26 guidance, management spoke of 'positive volume growth in both segments.' This quarter, Crop is now 'very marginal growth, mid-to-high single digit.' That's a strategic reset: end-customer weakness is acknowledged as structural, not cyclical. Management is de-emphasizing Crop investment and repositioning the company as a pharma-led portfolio — Pharma + Animal Health + Personal Care = 70–80% of the business by FY30, with Crop relegated to 20–30%.
Pharma CAGR lifted; new divisional targets introduced. Pharma is now projected to grow at 18–19% CAGR (vs. company 14–16%), driven by CDMO partnerships, DMF filings doubling from 2–3 to 5–6 per year, and new geographies (Japan, Latin America). Animal Health is being held to ₹400 crore by FY30 at 20%+ EBITDA margins. Personal Care is targeted at ₹200 crore by FY30 at >20% EBITDA margins — both specific, quantified for the first time.
FY28 positioned as the real inflection. Management framed FY27 as a 'transition year' — remediation costs are depressing fixed costs and EBITDA, but once the FDA clears (year-end FY27), those costs vanish. FY28 is where 'real meaningful numbers' emerge. This reframes the story from 'Q1 miss' to 'Q1 trough; watch FY28.'
EBITDA stable at 9.2%, operations running solid
Pharma YoY growth confirmed; CDMO partnerships accelerating
Animal Health ₹100Cr+ achieved; targeting ₹400Cr FY30
FDA remediation on track; zero customer losses in 12 months post-warning
Debt reduction track record (₹130Cr over 2 years)
Reported PAT negative (-₹7.4Cr); leverage is the primary drag
Crop division EBIT negative in Q1; structurally weak end-customer base
Pharma capacity utilization only 55–60%; recovery upside contingent on ramp
FY27 guidance (14–16% growth, 25–30% EBITDA growth) is conditional on Q2+ execution
FII ownership collapsed 5.36% → 0.99% in one year; institutions not convinced
FDA re-inspection delayed beyond year-end
HighRemediation costs (₹15–20Cr annualized) extend into FY28, delaying margin recovery. FY27 EBITDA guidance unachievable if clearance slips.
Crop Protection structural weakness persists
HighPricing pressure, end-customer distress (5–6 big players = 80% of market), Chinese competition. Even if Pharma + Animal Health hit targets, Crop headwinds could offset gains. EBITDA growth target of 25–30% becomes unachievable if Crop margin turns negative again.
Geopolitical raw material/energy cost volatility
HighQ1 saw ₹7–8Cr cost impact from Middle East tensions. If geopolitical escalates, margin guidance evaporates. Crop has zero pricing power to pass through.
High leverage and tight interest coverage
HighD/E 0.53, interest coverage <1x. Even if EBITDA grows to ₹46–50Cr (25–30% target), PAT remains negative if interest costs don't decline. Debt service is a hard ceiling on shareholder returns.
Unproven new business scaling
MediumAnimal Health ₹400Cr by FY30 (4x from ₹100Cr), Personal Care ₹200Cr by FY30 — both are greenfield or early-stage. Execution risk on CDMO contract wins, customer commercialization timelines, market acceptance.
How the street is positioned — and what it's saying
The market's verdict on Q1 was skeptical. The stock rallied +2.06% on day 1 (with 60.6% retail delivery), but that pop faded: by day 3 it was -1.56%, and by day 5 it had fallen to -2.29%. The initial relief — 'FDA remediation is on track, Pharma is recovering' — gave way to caution. At ₹217.99, the stock trades below its 20-day average (₹221.16) but above its 200-day average (₹208.91), pinned in no-man's-land between near-term skepticism and longer-term recovery hopes. It's down 16.48% from its all-time high but up 49% from the 52-week low — neither cheap nor expensive on technicals alone.
The real tell is the FII exit. Institutional ownership has collapsed from 5.36% in Q1 FY26 to just 0.99% in Q1 FY27 — a loss of 4.37 percentage points in one year. This is NOT the action of confident institutions. It signals: 'We like the Pharma story, but not at this leverage level, and not until Crop stabilizes.' DII ownership is stable at ~7%, suggesting domestic retail and HNIs are holding. But the FII vote of no-confidence is the canary in the coal mine: if institutions don't trust the near-term execution, the story has to prove itself on numbers, not narrative.
What to watch next — the proof points
1 · Q2 revenue guidance and capacity utilization
Management guided Q2 as 'substantially higher growth' YoY. The proof is in the number: if Q2 hits ~₹450Cr+ (vs. Q1's ₹402.8Cr, roughly +12%+ sequentially), and Pharma capacity utilization moves to 65–70%, the recovery narrative holds. If Q2 guidance is modest or utilization stays stuck, the trough is deeper than expected.
2 · Crop division stabilization
Crop EBIT of -₹6Cr in Q1 is unsustainable. Q2 will tell if the ₹7–8Cr raw material cost headwind moderates (oil prices stabilize) or persists. If Crop EBIT moves to flat or positive, the diversification strategy gains credibility. If it stays negative, Crop becomes a sink, and the company's growth story rests entirely on unproven new businesses.
3 · FDA re-inspection timeline and regulatory signals
Management is targeting year-end FY27 clearance. By Q2 results, there should be an update: is the re-inspection scheduled? Are there new open issues? Zero slippage is bullish; any delay signals FY28 is the real inflection, not FY27.
Hikal is a solid company executing a plausible turnaround, but it's not a home run yet. Operations are fine — EBITDA 9.2%, Pharma growing, new businesses launching. The problem is leverage (D/E 0.53, interest coverage Hold for existing holders — patience is needed for FY27 to Q4, when FDA clearance is expected and FY28 margins can be modeled. New entry is premature; wait for FDA clearance confirmation and Q2 Crop stabilization.
The single number to track: Pharma capacity utilization in H2 FY27. If it accelerates to 70%+, EBITDA can hit the 25–30% growth guidance. If it stays at 55–60%, FY27 remains a trough, and the real story is FY28. Current stock price offers limited margin of safety until that utilization proof point arrives.
Pharma recovery on track; near-term earnings under pressure
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
EBITDA and revenue numbers verified. Pharma YoY growth confirmed. Animal Health and Personal Care targets are specific but unproven at scale. FDA on track (no re-inspection delay yet). Crop weakness is new headwind not previously emphasized.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Hikal is executing a multi-year turnaround anchored on FDA remediation completion (expected by year-end FY27), Animal Health scaling (₹100Cr→₹400Cr by FY30), and Personal Care launch. Q1 was a trough due to planned FDA shutdown; recovery is on track. However, net loss (-₹7.4Cr), soft 5.9% YoY growth, and ₹7–8Cr Crop cost headwind underscore near-term margin pressure, partially offset by EBITDA stability at 9.2%. Key risk: Crop Protection remains structurally weak (pricing pressure, Chinese competition); if this doesn't stabilize in H2, full-year margin guidance of 25–30% EBITDA growth becomes unachievable.
₹402.8 Cr
Revenue · +5.9% YoY₹-7.4 Cr
Reported PAT · +67% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Pharma delivered YoY growth despite planned FDA shutdown
METPharma ₹233Cr revenue (Q1 is transition quarter); overall 5.9% YoY growth confirms Pharma outpaced Crop
Improving product mix and gross margins for Pharma division
MixedDivisional margins may improve, but company EBITDA 9.2%, PAT -1.8% due to ₹50Cr+ interest on ₹685Cr net debt
Zero customer losses; 86 audits, re-approvals by all 3 global regulatory bodies
METNo contradicting evidence; claim is credible and supported by re-approval narrative
FY27 growth 14–16%, EBITDA growth 25–30%, driven by Pharma + Animal Health + Personal Care
MixedQ1 is trough (5.9% YoY) due to FDA shutdown. Q2+ expected to recover substantially. Guidance conditional on recovery execution.
Earnings quality
What changed since the last call
Crop Protection growth outlook downgraded to 'marginal'
DowngradePrior call: 'positive volume growth in both segments.' Q1 call: 'very marginal growth, mid-to-high single digit.' End-customer weakness (5–6 big players = 80% of market) is structural, not cyclical.
Pharma CAGR elevated; expected to outpace company CAGR
UpgradeQ1 call: Pharma expected 18–19% CAGR (vs company 14–16%). Prior call did not quantify divisional CAGR. CDMO acceleration and new geographies (Japan, Latin America) are the driver.
Personal Care and Animal Health multi-year guidance clarified with specific revenue/margin targets
NewPrior call: 'entering Personal Care, scaling Animal Health.' Q1 call: Personal Care ₹200Cr, >20% EBITDA by 3 years; Animal Health ₹400Cr, 20%+ EBITDA by FY30. Concrete targets introduced.
FY28 expected to be 'substantially better' than FY27
NeutralManagement: 'real meaningful numbers will be in FY28 and beyond' due to remediation cost removal. FY27 remains a transition year. Not a change to guidance, but a reframing of expectations.
The Q&A
Analysts (Aman Vora, Rohit Sinha) pushed hard on the margin gap: if Pharma is growing 18–19% CAGR and Crop is marginal, why isn't company EBITDA margin better than 25–30% growth? Sameer held firm, explaining remediation costs are depressing FY27 EBITDA, real improvement comes in FY28. On Crop pricing, Rohit asked about contract revision; Sameer acknowledged only partial pass-through due to end-customer price inelasticity. On FDA, Raghuram pressed confidence; Sameer detailed stage-gate approach, 3 regulatory re-approvals, 86 customer audits, zero lost contracts. Management handled pushback well, transparent on headwinds.
Animal Health margins — Aman Vora, Premium Capital
Answered20% plus EBITDA margins once operational leverage is reached.
Crop Protection outlook — Aman Vora, Premium Capital
AnsweredVery marginal growth (mid-to-high single digit). End-customers (5–6 big players = 80% of market) are weak. Diversifying into Animal Health, Personal Care; not investing significant new capital in Crop.
Company repositioning — Aman Vora, Premium Capital
AnsweredYes. Shifting to 4-division model (Pharma, Animal Health, Personal Care, Crop). Pharma + allied (human + non-human + skincare) = 70–80% of business by next 2–3 years; Crop = 20–30%.
Personal Care guidance — Aman Vora, Premium Capital
Answered₹200Cr revenue by 3 years post-launch (i.e., by FY30). EBITDA margins >20%, in line with Pharma.
Margin guidance reconciliation — Aman Vora, Premium Capital
AnsweredFY27 is a transition year; FDA remediation costs are depressing fixed costs and EBITDA. Once remediation ends, FY28 onwards EBITDA will improve substantially. Real meaningful numbers in FY28+.
FDA clearance and FY28 revenue — Rohit Sinha, Sunidhi Securities
PartialGuidance will accelerate in FY28 due to pending approvals. Filings pending FDA approval will be completed post-remediation, driving revenue ramp in FY28 with better margins.
Crop pricing pass-through — Rohit Sinha, Sunidhi Securities
AnsweredSome contracts have pass-through; competitive ones don't. End-customer (farmer) prices don't increase much; no price elasticity. In Q1 alone, ₹7–8Cr raw material/energy cost impact. Mixed bag; hoping oil prices stabilize.
Forward CAGR and margin profile — Rohit Sinha, Sunidhi Securities
AnsweredExpecting 15–16% CAGR to continue. Fixed costs won't scale at this level; next year remediation cost benefit will improve P&L. FY28 substantially better than FY27, which is better than FY26.
FDA remediation confidence — Raghuram Kuchi, Bestpals Research & Advisory
AnsweredStage-gate approach; continuous dialogue with FDA on bi-monthly/quarterly basis. FDA feedback: moving in right direction, few open issues to close. After August 2025 warning, 3 big regulatory bodies and 86 customers have audited and re-approved. Putting controls, systems, training, SOPs, continuous audits.
Pharma CAGR post-FDA — Raghuram Kuchi, Bestpals Research & Advisory
PartialCAGR will improve. If company is at 14–15% CAGR, Pharma will be 18–19% CAGR going forward, maybe even faster if approvals ramp and NCE filings accelerate.
Animal Health FY30 target — Raghuram Kuchi, Bestpals Research & Advisory
Answered₹400Cr revenue by FY30, based on strategic plan and current customer traction.
Animal Health export markets — Raghuram Kuchi, Bestpals Research & Advisory
AnsweredGlobally agnostic. Customers are pharma innovators, so sell to all markets where they sell: US, Europe, Japan, ROW (Latin America, etc.).
Guidance
FY27: 14% to 16% growth on FY26 base (implies ₹777–787Cr)
MediumQ1 is trough (5.9% YoY); Q2+ expected substantial recovery. Q2 specifically called as 'substantial growth' YoY. H2 benefiting from CDMO ramp, Crop normalization, Personal Care launch.
EBITDA growth 25–30% for FY27 (implying ₹46–50Cr EBITDA, vs Q1's ₹37Cr)
MediumQ2-Q4 recovery expected to drive ≥20% EBITDA margins in H2. Pharma gross margin improving, Crop cost headwinds expected to moderate. Personal Care/Animal Health ramp supports leverage.
Pharma CAGR 18–19% (vs company 14–16%) going forward post-FDA
MediumNew geographies (Japan, Latin America), NCE filings accelerating, CDMO partnerships. But contingent on FDA clearance and no further customer losses.
Continued selective de-bottlenecking and capacity-building for Animal Health, Personal Care at ₹45–50Cr/quarter
High4-year ₹900Cr investment program (₹300Cr maintenance, ₹600Cr growth). Retooled Crop asset now serving Pharma/Animal Health, reducing execution time by 12 months. ROI-focused allocation.
Risks the call surfaced
Regulatory/FDA clearance
HighRemediation plan on track but re-inspection depends on FDA scheduling. If delayed beyond Q4 FY27, remediation costs extend, margin recovery pushed to FY29.
Crop Protection structural decline
HighIndustry end-customers (5–6 big pharma/agrochemical players = 80% of market) are weak; pricing under pressure; Chinese supply creates race-to-bottom. Management acknowledges 'very marginal growth' (mid-to-high single digit) going forward. Q1 margins already negative (-₹6Cr EBIT) due to ₹7–8Cr raw material cost.
Geopolitical raw material/energy volatility
MediumQ1 saw ₹7–8Cr cost impact from geopolitical tensions in Middle East (fuel, raw material costs). If tensions persist or escalate, EBITDA growth target of 25–30% becomes unachievable.
High leverage / leverage-driven losses
MediumCompany generated ₹37Cr EBITDA but lost ₹7.4Cr in PAT due to ₹50Cr+ annual interest on net debt. Even if EBITDA grows to ₹46–50Cr (25–30% growth), PAT may remain negative if interest costs don't decline. Leverage is the primary margin headwind.
Unproven new business scaling
MediumAnimal Health targeting ₹400Cr by FY30 (4x from ₹100Cr FY26) at 20%+ EBITDA. Personal Care targeting ₹200Cr by FY30 with >20% EBITDA. Both are new/emerging; scale and margin realization unproven. Dependence on CDMO contract wins, customer commercialization timelines, market acceptance.
Management
Score 7/10. Clear and transparent. Sameer articulates strategy (shift from chemical to 4-division pharma-led company) with specific revenue/margin targets. Honest about headwinds (FDA costs, Crop weakness, leverage). Divisional heads provide granular numbers (capacity, margins, pipeline details). Solid operational track record. FDA remediation on track (zero customer losses, 86 audits, 3 regulatory re-approvals). Animal Health scaled to ₹100Cr in 5–6 years. Debt reduced ₹130Cr over 2 years. But Q1 net loss and 5.9% YoY growth fall short of 14–16% full-year guidance, though Q1 is acknowledged trough.
1 · End of FY27
FDA re-inspection and clearance; removes ₹15–20Cr annualized remediation costs
2 · H2 FY27
CDMO orders ramp (deferred from H1), Crop volumes normalize, Personal Care revenue starts
3 · FY28
Remediation cost removal + higher capacity utilization drive EBITDA margin expansion to 15–17%+ (vs 9.2% Q1)
Key risk: Crop Protection remains structurally weak (pricing pressure, Chinese competition); if this doesn't stabilize in H2, full-year margin guidance of 25–30% EBITDA growth becomes unachievable.